The company can say whatever they want, and it’s in their best interest to talk things up. However, just because they put something in a presentation doesn’t make it true. I have yet to find any other source suggesting that +20 million echocardiograms are performed in the US each year. The circa 7 million figure is the most consistent reference I have found online across a variety of sources.
On a positive note, regardless of the exact figure, the number of echocardiograms performed is increasing each year, as the overall health of Americans continues to decline. Additionally, when a cardiologist orders an echocardiogram, they are typically looking for a comprehensive assessment rather than focusing on a single condition like aortic stenosis or heart failure.Hospitals are also financially incentivised to test for both, they get paid to perform the test, and diagnosing either condition (aortic stenosis or heart failure) creates opportunities to bill for further procedures. On top of that, pharmaceutical companies have a vested interest in selling more medications, so the entire system is incentivised to identify and treat these conditions.All of this suggests that, provided a company like EIQ successfully integrates its software into a hospital system and secures reimbursement codes for both conditions, they will generate income for both diagnostic tools.
EIQ Price at posting:
25.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)